Genomic testing links 'exceptional' drug response to rare mutations in bladder ... EurekAlert (press release) BOSTON -- A patient with advanced bladder cancer in a phase I trial had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute researcher, and genomic ... |
